These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan. Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer. Hamza S; Dancourt V; Lejeune C; Bidan JM; Lepage C; Faivre J Eur J Cancer; 2013 Aug; 49(12):2727-33. PubMed ID: 23601670 [TBL] [Abstract][Full Text] [Related]
6. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study. Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978 [TBL] [Abstract][Full Text] [Related]
7. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431 [TBL] [Abstract][Full Text] [Related]
8. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. Lieberman DA; Weiss DG; N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208 [TBL] [Abstract][Full Text] [Related]
9. Improvements in colorectal cancer screening programmes - quantitative immunochemical faecal occult blood testing - how to set the cut-off for a particular population. Kovarova JT; Zavoral M; Zima T; Zak A; Kocna P; Kohout P; Granatova J; Vanickova Z; Vranova J; Suchanek S; Benes Z; Celko MA; Povysil C Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):143-50. PubMed ID: 22837135 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). Chen LS; Liao CS; Chang SH; Lai HC; Chen TH J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564 [TBL] [Abstract][Full Text] [Related]
11. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program. Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A; Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264 [TBL] [Abstract][Full Text] [Related]
12. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450 [TBL] [Abstract][Full Text] [Related]
13. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Smith A; Young GP; Cole SR; Bampton P Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938 [TBL] [Abstract][Full Text] [Related]
14. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME; N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205 [TBL] [Abstract][Full Text] [Related]
15. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?]. Quintero E Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340 [TBL] [Abstract][Full Text] [Related]
16. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Haug U; Hundt S; Brenner H Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091 [TBL] [Abstract][Full Text] [Related]
17. A comparative study of immunochemical fecal tests for detection of colorectal adenomatous polyps. Nakama H; Fattah A; Zhang B; Uehara Y; Wang C Hepatogastroenterology; 2000; 47(32):386-9. PubMed ID: 10791196 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Berchi C; Guittet L; Bouvier V; Launoy G Int J Technol Assess Health Care; 2010 Jan; 26(1):48-53. PubMed ID: 20059780 [TBL] [Abstract][Full Text] [Related]
19. A prospective study of a new immunochemical fecal occult blood test in Korean patients referred for colonoscopy. Woo HY; Mok RS; Park YN; Park DI; Sung IK; Sohn CI; Park H Clin Biochem; 2005 Apr; 38(4):395-9. PubMed ID: 15766742 [TBL] [Abstract][Full Text] [Related]
20. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]